HYBRID TYPE 1 EFFECTIVENESS-IMPLEMENTATION TRIAL FOR PRIMARY CARE DEPRESSION SCREENING AND REFERRAL TO A REMOTE DIGITAL MENTAL HEALTH CLINIC
HYBRID TYPE 1 EFFECTIVENESS-IMPLEMENTATION TRIAL FOR PRIMARY CARE DEPRESSION SCREENING AND REFERRAL TO A REMOTE DIGITAL MENTAL HEALTH CLINIC
批准号:
10375031
负责人:
Nicholas Peiper
金额:
$74.97万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-04-07 至 2023-03-31
关键词:
AdministratorAdultAffectAftercareAntidepressive AgentsAnxietyAppointmentAttitudeBehavioralBiofeedbackCaringClinicClinicalClinical TrialsCognitive TherapyCommunicationCompetenceDataDepressed moodDepression screenDevicesEffectivenessEnrollmentEnsureFeedbackFutureHealthHealth ProfessionalHealthcare SystemsHybridsImpairmentImprove AccessIndividualInterventionInterviewKnowledgeMaterials TestingMeasuresMedicalMental DepressionMental HealthMental Health ServicesMental disordersMethodsModalityModelingMotivationNutritionalOutcomeParticipantPatient CarePatientsPatternPersonsPharmacologyPhasePlaguePopulationPreparationPrimary Health CareProceduresProcessProductivityProviderPsychiatristPsychiatryRandomizedRandomized Controlled TrialsReportingResearchResearch DesignScheduleSeveritiesSiteSleepSmall Business Innovation Research GrantSpecificitySurveysSystemTestingTimeTrainingTransportationUnited StatesWorkbarrier to carebaseburnoutcare providerscare seekingclinically significantcohortcollaborative carecomorbiditycontextual factorscostdepressive symptomsdesigndigital healthdigital mental healthdisabilityeffectiveness implementation trialeffectiveness testingexperienceheart rate variabilityhelp-seeking behaviorimplementation determinantsimplementation facilitatorsimprovedinformation gatheringintervention programmindfulness meditationmobile applicationpeerphase 2 studypost interventionprimary care settingprimary outcomeprocess evaluationprogramspsychologicrecruitresearch clinical testingresponsesatisfactionscreeningside effectsingle episode major depressive disordersocial stigmastandard caretreatment as usualtreatment program
中文摘要
摘要
全球抑郁症的负担令人震惊:据估计,#年美国成年人口中有7%至10%受到影响
在任何一年,抑郁症的高并存率以及与功能受损和
残疾每年给美国造成的损失约为2000亿美元。问题继续困扰着筛查、识别、
以及在初级保健环境中治疗抑郁症。抑郁症患者被认为是这样的,较少
在美国,超过一半的时间,准确识别患者的敏感度为49.2%,特异度为81.1%
目前有严重的抑郁发作。抑郁症的治疗通常从初级保健提供者开始
然而,开抗抑郁药和使用协作护理模式,患者会遇到许多障碍
治疗费用高、求助尴尬、预约等待时间长等问题。这些
治疗也被证明只有短期效果,患者仍在寻求治疗
没有找到可获得的有效解决方案来缓解他们的抑郁症状。
Meru Health Medical,P.A.开发了一套完整的、经过临床验证的抑郁症治疗方案,
焦虑和疲惫会带来长期的后果。Meru Health Program(MHP)是一个为期12周的移动应用程序-
基于在线数字心理健康诊所,由有执照的临床治疗师和精神病学家监督。快递
寻求克服许多阻碍接受心理健康服务的障碍,如
因为获得更好的机会和更少的耻辱。这个SBIR直接到第二阶段的应用旨在进行多站点
MHP在筛查抑郁症阳性成年人中的混合型1型随机对照试验(RCT)
初级保健为该计划的快速传播做好准备。这个应用程序提供了一个概念验证
研究开发和优化学习材料,测试筛选、推荐和学习注册程序
为300名患者的多部位随机对照试验做准备。随后,对交付进行多个利益相关者过程评估
将进行MHP干预,以指导后续研究的建立并更好地了解
实施的背景因素。
研究设计允许同时测试临床干预对相关疾病的有效性
结果,同时观察和收集有关执行情况的信息,这是该计划快速实施所必需的
传播。MHP的独特好处在于它对接受治疗的患者进行了谨慎的给药
计划中使用的模式和方法,通过高质量的研究得到验证,这些研究表明
效率。Meru Health Medical,P.A.致力于以诚信进行尖端研究,作为一种
持续改进MHP。这项申请将确定通过直接转介到MHP的可行性
在初级保健环境中进行筛查,使转向初级保健的美国成年人的高比例受益
寻求抑郁症长效治疗方法的医疗保健专业人员。
英文摘要
ABSTRACT
The global burden of depression is staggering: Affecting an estimated 7 to 10% of the adult U.S. population in
any given year, depression’s high rates of comorbid conditions and association with impaired functioning and
disability costs the U.S. approximately $200 billion per year. Issues continue to plague screening, recognition,
and treatment for depression in primary care settings. Patients with depression are recognized as such, less
than half of the time in the U.S, with 49.2% sensitivity and 81.1% specificity for accurately identifying patients
having a current major depressive episode. Treatment for depression usually begins with primary care providers
prescribing antidepressants and use of collaborative care models, however, patients experience many barriers
to these treatments such as high costs, embarrassment in seeking help, and long waits for appointments. These
treatments have also been shown to have only a short-term effect, and patients continue seeking treatment
without finding an accessible and effective solution to alleviate their depressive symptoms.
Meru Health Medical, P.A. developed a complete and clinically proven treatment program for depression,
anxiety, and burnout with long-lasting outcomes. The Meru Health Program (MHP) is a 12-week, mobile app-
based online digital mental health clinic overseen by a licensed clinical therapist and a psychiatrist. The delivery
of the MHP seeks to overcome many of the barriers that can hinder the receipt of mental health services such
as improved access and less stigma. This SBIR Direct-to-Phase II application is aimed to conduct a multi-site
Hybrid Type 1 Randomized Control Trial (RCT) of the MHP among adults who screen positive for depression in
primary care to prepare for the program’s rapid dissemination. This application proposes a proof-of-concept
study to develop and optimize the study materials, test the screening, referral, and study enrollment procedures
in preparation for a 300-patient multisite RCT. Following, a multistakeholder process evaluation of the delivery
of the MHP intervention will be conducted to guide the set-up of subsequent studies and to better understand
contextual factors for implementation.
The study design allows simultaneous testing of the effectiveness of the clinical intervention on relevant
outcomes while observing and gathering information on implementation which is requisite for the program’s rapid
dissemination. The unique benefit of the MHP is in its discreet administration to patients with the treatment
modalities and approaches utilized in the program, validated by high quality studies showing significant proof of
efficiency. Meru Health Medical, P.A. is committed to cutting-edge research conducted with integrity as a way to
continuously improve the MHP. This application will establish the feasibility of referral to the MHP via direct
screening in a primary care setting, benefiting the high percentage of U.S. adults turning to primary care
healthcare professionals who seek a long-lasting treatment method for depression.
期刊论文(6)
专著(0)
科研奖励(0)
会议论文
海外基金